---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Natural history, survival, and mortality"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Natural history, survival, and mortality. Topics: Stage at diagnosis and five-year relative survival, all oral cavity and pharynx cancer; Stage at diagnosis and five-year relative survival, all laryngeal cancer; Estimated U.S. deaths in 2026 and death rate, all oral cavity and pharynx cancer; Estimated U.S. deaths in 2026 and death rate, all laryngeal cancer; 9 further topics. 13 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Stage at diagnosis and five-year relative survival, all oral cavity and pharynx cancer

| SEER stage | Percent of cases | Five-year relative survival |
| --- | --- | --- |
| Localized | “26%” | “88.7%” |
| Regional | “55%” | “69.7%” |
| Distant | “12%” | “36.0%” |
| Unstaged | “6%” | “62.3%” |

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

> “5-Year Relative Survival 69.9%”

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

<a id="topic-2.2.1.3-2"></a>

### Stage at diagnosis and five-year relative survival, all laryngeal cancer

| SEER stage | Percent of cases | Five-year relative survival |
| --- | --- | --- |
| Localized | “49%” | “79.8%” |
| Regional | “30%” | “49.4%” |
| Distant | “15%” | “36.0%” |
| Unstaged | “6%” | “57.0%” |

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

> “5-Year Relative Survival 62.5%”

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-2.2.1.3-3"></a>

### Estimated U.S. deaths in 2026 and death rate, all oral cavity and pharynx cancer

> “The death rate was 2.7 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)

> “13,150 people will die from the disease”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.3-4"></a>

### Estimated U.S. deaths in 2026 and death rate, all laryngeal cancer

| Measure | Quoted value |
| --- | --- |
| Estimated deaths in 2026 | “3,960” |

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

> “The death rate was 0.9 per 100,000 men and women per year.”

Source: [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)

<a id="topic-2.2.1.3-5"></a>

### U.S. mortality trends, all oral cavity and pharynx cancer

> “After decades of decline, the mortality rate for cancers of the oral cavity and pharynx combined increased by 0.8% per year from 2009 through 2023, driven by an increase of about 2% per year in deaths from cancers of the tongue, tonsil, and oropharynx, most of which are associated with HPV.”

Source: [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.3-6"></a>

### Survival trend attributed to the changing share of smoking-related cancers, all oral cavity cancer

> “For example, the increase in survival for people diagnosed with oral cavity cancers from 58% in the mid‐1990s to 69% in 2015–2021 partly reflects a decreased proportion of smoking‐related cancers and an increased proportion of HPV infection‐associated cancers, which typically have a better prognosis.”

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.3-7"></a>

### Global deaths in 2024 by subsite, all histologies

| GLOBOCAN 2024 cancer site | Deaths | Percentage of all deaths |
| --- | --- | --- |
| Lip, oral cavity | “194,108” | “2.0” |
| Larynx | “96,619” | “1.0” |
| Oropharynx | “51,823” | “0.5” |
| Hypopharynx | “49,748” | “0.5” |

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.3-8"></a>

### HPV-negative versus HPV-positive survival, locally advanced oropharyngeal cancer treated with chemoradiotherapy

> “The 3-year rates of overall survival were 82.4% (95% CI, 77.2 to 87.6) in the HPV-positive subgroup and 57.1% (95% CI, 48.1 to 66.1) in the HPV-negative subgroup”

Source: [Ang et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2943767/)

<a id="topic-2.2.1.3-9"></a>

### HPV-negative versus HPV-positive survival, population-based U.S. oropharyngeal cancer

> “Median survival was significantly longer for HPV-positive than for HPV-negative patients (131 v 20 months; log-rank P < .001; adjusted hazard ratio, 0.31; 95% CI, 0.21 to 0.46). Survival significantly increased across calendar periods for HPV-positive (P = .003) but not for HPV-negative patients (P = .18).”

Source: [Chaturvedi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3221528/)

<a id="topic-2.2.1.3-10"></a>

### Survival after recurrence of locoregionally advanced HNSCC in U.S. adults aged 66 years or older

> “Within the resected cohort, patients with recurrence had a median OS of 23.8 months vs 44.4 months for patients without recurrence (P = 0.008); the 5-year OS rate was 30.2% compared with 42.5%, respectively”
> “Similarly, in the unresected cohort, the median OS was 23.7 months for patients with recurrence compared with 64.5 months for those without (P < 0.001), and the 5-year OS rate was 30.6% compared with 50.8%, respectively”

Source: [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

<a id="topic-2.2.1.3-11"></a>

### Median overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC at 4-year follow-up

> “The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).”
> “The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population (HR, 0.71; 95% CI, 0.59 to 0.85; nominal one-sided P = .00008; Figs 2D-2F).”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.1.3-12"></a>

### Five-year overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC

> “The 5-year OS rate in the total population was 14.4 % for pembrolizumab versus 6.5 % for EXTREME and 16.0 % for pembrolizumab-chemotherapy versus 5.2 % for EXTREME.”

Source: [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/)

<a id="topic-2.2.1.3-13"></a>

### Real-world overall survival with first-line pembrolizumab by HPV status in recurrent or metastatic HNSCC

> “Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors”
> “Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

Additional sources: [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
